Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Indexes  >  USA  >  S&P 500    SP500

S&P 500

Real-time Estimate Quote. Real-time Estimate TTM Zero - 06/01 06:48:05 pm
3057.89 PTS   +0.45%
12:35pWALL STREET STOCK EXCHANGE : Stocks Start Week With Modest Gains
12:25pWorld equities edge higher despite U.S.-China tensions
12:18pWorld equities edge higher despite U.S.-China tensions
News SummaryAll newsNews of the components ofMarketScreener Strategies

Wall Street Week Ahead: Investors look beyond drug makers as hunt for COVID-19 treatment heats up

share with twitter share with LinkedIn share with facebook
share via e-mail
05/23/2020 | 09:03am EDT
Morning commuters are seen on Wall St. outside the NYSE in New York

By David Randall

Investors are diversifying bets in the healthcare sector, as the rush to develop treatments for Covid-19 has driven up prices for some pharmaceutical stocks.

A record 48% of fund managers are overweight healthcare stocks, a BofA survey showed, and the S&P 500 healthcare sector is up nearly 34% since its March low. Hopes for a treatment have also sparked outsize rallies in the shares of companies such as Moderna and Inovio Pharmaceutcials, up 253% and 327% since the start of the year, respectively, as of Friday's close.

In recent weeks, news of potential treatments or vaccines to fight the pandemic have occasionally fueled swings in broader markets.

Yet some fund managers believe lasting profits may be elusive for vaccine-makers, leading them to seek corners of the healthcare sector that could see longer-term benefits from the fight against coronavirus.

Large pharmaceutical companies such as Johnson & Johnson and GlaxoSmithKline Plc have said they plan to make any successful vaccine available at cost, though they could reap profits later if a seasonal shot is needed. Multiple treatments could also divide the market between many players, investors said.

"There's the question of 'Does anyone really make a lot of money on this?," said Larry Cordisco, co-portfolio manager of the Osterweis Fund.

Signs of progress on potential treatments could bolster the case for a quicker economic recovery and further fuel the rally that has boosted the S&P 500 around 30% from its late March lows. In the next two weeks, Gilead Sciences is expected to announce results of clinical studies of its potential coronavirus treatment remdesivir for patients with moderate symptoms of Covid-19. Pfizer has said it expects to release safety data for initial human testing of experimental vaccine by the end of May.

Cordisco is looking further afield. One of the companies he owns is medical device maker Danaher Corp, which manufactures a rapid Covid-19 test the FDA approved in March. Its shares are up 3.1% since the start of the year.

"If you're looking for where the profits might be in the chain, it's somebody like that who is going to benefit. They can cash in the whole way," Cordisco said.

Alessandro Valentini, portfolio manager at Causeway Capital Management, said his firm is looking for value opportunities as the healthcare sector becomes more expensive, trading now at 22.9 times trailing earnings, slightly more than the 21.9 multiple of the S&P 500 index as a whole.

He is staying away from potential vaccine producers in favor of companies such as Takeda Pharmaceutical Co Ltd. Japan's largest pharmaceutical company said this month it could start clinical trials as early as July for a COVID-19 treatment based on antibodies from blood of recovered patients.

"This is a company that will be part of the solution and can buy a world class business for a significant discount to what we think the fair value is," Valentini said. Its shares are down nearly 6.5% for the year to date.

Mike Caldwell, a portfolio manager of the Driehaus Event Driven Fund, said his fund is focusing on supply chains of vaccine production rather than the drug companies themselves.

He is betting on companies such as Roche Holding and Abbott Laboratories, which have large diagnostics businesses that will likely be a part of any future COVID-19 treatment.

He is also bullish on smaller companies such as Luminex Corp, which received an FDA emergency use authorization for its COVID-19 diagnostic test. Shares are up 36% year to date.

"With so many players who have meaningful resources, it's hard to predict what the ultimate market share of any one approach will be," he said.

(Reporting by David Randall; Editing by Ira Iosebashvili and David Gregorio)

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -2.29% 92.7152 Delayed Quote.9.28%
DANAHER CORPORATION -0.70% 165.43 Delayed Quote.8.55%
DJ INDUSTRIAL 0.29% 25456.56 Delayed Quote.-11.06%
GILEAD SCIENCES -3.76% 74.895 Delayed Quote.19.78%
GLAXOSMITHKLINE PLC -0.60% 1661.8 Delayed Quote.-7.11%
LUMINEX CORPORATION 0.22% 31.23 Delayed Quote.34.54%
NASDAQ 100 0.24% 9582.06195 Delayed Quote.9.42%
NASDAQ COMP. 0.55% 9542.902505 Delayed Quote.5.77%
PFIZER LIMITED -0.89% 4013.65 End-of-day quote.-4.98%
PFIZER, INC. -7.84% 35.305 Delayed Quote.-2.53%
ROCHE HOLDING AG -2.51% 332.7 Delayed Quote.5.96%
S&P 500 0.33% 3054.45 Delayed Quote.-5.77%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.84% 4114 End-of-day quote.-5.03%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on S&P 500
12:35pWALL STREET STOCK EXCHANGE : Stocks Start Week With Modest Gains
12:25pWorld equities edge higher despite U.S.-China tensions
12:18pWorld equities edge higher despite U.S.-China tensions
12:14pWorld equities edge higher despite U.S.-China tensions
11:55aWall St. flat as recovery hopes offset U.S. protests, China tensions
11:09aPfizer Down Nearly 8%, on Pace for Largest Percent Decrease in Over 11 Years ..
10:36aWALL STREET STOCK EXCHANGE : U.S. Stocks Waver as China Tensions Threaten to Fla..
09:49a'Lemon' or not, Trump is stuck with Phase 1 China trade deal
09:48aWALL STREET STOCK EXCHANGE : U.S. Stocks Open Lower as China Tensions Threaten t..
09:16aNEWS HIGHLIGHTS : Top Global Markets News of the Day
More news
Chart S&P 500
Duration : Period :
S&P 500 Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends S&P 500
Short TermMid-TermLong Term
Top / Flop S&P 500
COTY INC. 4.325 Real-time Estimate Quote.19.15%
CAPRI HOLDINGS LIMITED 17.075 Real-time Estimate Quote.13.53%
GAP INC 10.015 Real-time Estimate Quote.12.53%
NORWEGIAN CRUISE LINE HOLDINGS LTD. 17.075 Real-time Estimate Quote.9.04%
KIMCO REALTY CORPORATION 11.985 Real-time Estimate Quote.7.88%
VERIZON COMMUNICATIONS 55.915 Real-time Estimate Quote.-2.55%
NETAPP, INC. 43.02 Real-time Estimate Quote.-3.41%
GILEAD SCIENCES 75 Real-time Estimate Quote.-3.64%
NORTONLIFELOCK INC. 21.865 Real-time Estimate Quote.-4.02%
PFIZER, INC. 35.315 Real-time Estimate Quote.-7.53%
Heatmap :